MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • MDS Virtual Congress 2020

    Characterizing Global Cohorts with Monogenic Parkinson’s Disease

    E.J Vollstedt, S. Schaake, M. Kasten, K. Lohmann, C. Klein (Lübeck, Germany)

    Objective: To clinically and genetically characterize a global sample of subjects with monogenic Parkinson’s disease (mPD) and unaffected mutation carriers. Background: Publications on patients with…
  • MDS Virtual Congress 2020

    The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease

    E. Kozina, M. Byrne, L. Oakley, R. Smeyne (Philadelphia, PA, USA)

    Objective: To test the hypothesis the neurodegenerative cascade in the CNS that leads to Parkinson’s disease (PD) is initiated by signals emanating from the peripheral…
  • MDS Virtual Congress 2020

    Distinct compensatory and maladaptive wiring patterns in genotypic Parkinson’s disease

    K. Schindlbeck, A. Vo, N. Nguyen, A. Rommal, C. Tang, M. Niethammer, V. Dhawan, R. Saunders-Pullman, S. Bressman, D. Eidelberg (New York, NY, USA)

    Objective: Although disease networks have been identified in Parkinson’s disease (PD) using functional imaging, it is unclear whether these represent maladaptive or compensatory responses to…
  • MDS Virtual Congress 2020

    Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation

    S. Sambin, S. Lavisse, C. Decaix, G. Mangone, F. Cormier, B. Le Toullec, S. Lesage, P. Remy, A. Brice, J.C Corvol (Paris, France)

    Objective: To investigate the time course of modifications in dopaminergic terminals during the premotor phase in LRRK2 genetically determined Parkinson’s disease (PD). Background: Increased dopamine…
  • MDS Virtual Congress 2020

    Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations

    D. Jennings, P. LeWitt, D. Kern, I. Goodman, A. Siderowf, O. Omidvar, A. Ellenbogen, J. Aldred, R. Macuica, S. Huntwork-Rodriguez, C. Ho, M. Troyer (South San Francisco, CA, USA)

    Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…
  • MDS Virtual Congress 2020

    Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease

    J. Shirvan (Cambridge, MA, USA)

    Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…
  • MDS Virtual Congress 2020

    Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort

    T. Simuni, A. Siderowf, M. Brumm, C. Caspell, H. Cho, C. Coffey, T. Foroud, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, K. Marek, p. PPMI Investigators (Chicago, IL, USA)

    Objective: To examine longitudinal change in the clinical characteristics of non-manifesting LRRK2 mutation carriers (NMCs) compared to healthy controls (HC) in the Parkinson’s Progression Markers…
  • 2019 International Congress

    Investigating the cellular role of LRRK2 in the immune system

    I. Nazish, R. Bandopadhyay (London, United Kingdom)

    Objective: The objective of this project is to investigate the effect of Leucine Rich-Repeat Kinase 2 (LRRK2) dysfunction in the signalling mechanisms in macrophages and…
  • 2019 International Congress

    Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson’s disease

    G. Pagano, P. Vickers, J. Schulz, H. Wilson, M. Politis (London, United Kingdom)

    Objective: We hypothesised that abnormal sprouting of serotonergic terminals in the hypothalamus may lead to abnormal structural connectivity, which can be measured with diffusion tensor…
  • 2019 International Congress

    Genotype influences circuit compensation in Parkinson’s disease

    K. Schindlbeck, A. Vo, N. Nguyen, C. Tang, M. Niethammer, V. Dhawan, V. Brandt, R. Saunders-Pullman, S. Bressman, D. Eidelberg (Manhasset, NY, USA)

    Objective: This study investigates differences in brain network organization in patients with Parkinson’s disease (PD) with genetic risk factors relative to sporadic PD patients and…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Welcome to the MDS Abstracts Site
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • The hardest symptoms that bother patients with Parkinson's disease
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley